Badanie wpływu etidronianu disodowego na zwapnienia w zespole Fahr'a u pacjentów z zaburzeniami poznawczymi

Fahr's disease, also known as Fahr's syndrome, is a rare condition characterized by abnormal calcium deposits in certain areas of the brain. These deposits can lead to various symptoms, including problems with movement, cognitive decline, and psychiatric issues. The study aims to investigate whether a medication called etidronate disodium, taken in the form of oral capsules, can help slow down or reduce the worsening of cognitive functions in individuals with Fahr's disease or syndrome.

Participants in the study will receive either the etidronate disodium capsules or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be "double-blind," meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This approach helps ensure that the results are not influenced by expectations or biases.

The study will last for about 12 months, during which changes in cognitive function, mobility, psychiatric symptoms, daily functioning, quality of life, and brain calcification will be monitored. The primary goal is to see if etidronate disodium can effectively manage the symptoms associated with Fahr's disease or syndrome compared to the placebo.